Yes. They used to do profit-sharing cooperation, but later Novo Nordisk thought they were getting too much, so the two sides fell out. After the fallout, they started making their own generic drugs; this kind of platform company, even if it doesn't sell Novo Nordisk's products, can still find other small and medium-sized pharmaceutical manufacturers. It's just a matter of time.

Is it possible to cooperate and share the revenue?

HIMS was previously skirting the edge, using compounded drugs to bypass patent benefits, but the FDA clearly stated it would take decisive action against &#34;large-scale marketing of illegal generic drugs&#34; and directly named HIMS. With the $49 weight-loss drug taken off the shelves, what else can they sell?This doesn't feel like a problem of cheap valuation, but rather an issue of regulators not tolerating the grey area of compounded drugs. It's okay to bet on a rebound after an oversold drop, just don't fool yourself into thinking it's a value investment trap.$Hims &amp; Hers Health(HIMS.US)